Evercore ISI Assumes Travere Therapeutics (TVTX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Price: $52.31 +0.52%
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
12 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Evercore ISI analyst Gavin Clark-Gartner assumes coverage on Travere Therapeutics (NASDAQ: TVTX) with a Outperform rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Travere Therapeutics click here. For more ratings news on Travere Therapeutics click here.
Shares of Travere Therapeutics closed at $17.92 yesterday.
You May Also Be Interested In
- Raymond James Starts Quince Therapeutics Inc. (QNCX) at Outperform
- BNP Paribas Exane Starts BellRing Brands (BRBR) at Outperform
- Jefferies Starts Plains All American (PAA) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
